The licensing deal for BAFF/APRIL inhibitor telitacicept, which also includes regulatory and commercial milestones exceeding ...

Nektar, which accused Lilly of making errors in its analysis of the data, forged ahead with the programme and started the ...

It is not clear how AS01 might help lower the risk of dementia, but Oxford University said lab studies show that the adjuvant ...

This publication has not been sponsored or paid for by any external entities. The insights and perspectives shared are organic, reflecting the author's genuine viewpoints and professional expertise ...

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular ...

BIO 2025 this year came at a uniquely fraught moment for vaccination in the United States just days after HHS Secretary ...

Liquid biopsies are reshaping colon cancer detection, particularly in addressing the rise in early-onset cases.

As the CEO of ProofPilot, Chris Venezia has a track record of success with more than 18 years of strong leadership in product commercialisation, patient recruitment, marketing, and sales. He joined ...

Antisense-based therapy salanersen (BIIB115/ION306) is a possible follow-up to Biogen's big-selling Spinraza (nusinersen) therapy for SMA, which has come under pressure from increased competition in ...

Elevidys has been given full approval to treat ambulatory patients with DMD, with an accelerated approval in non-ambulatory ...

In a statement, Novo Nordisk said that it was terminating the collaboration "due to concerns about their illegal mass ...

Making good on his promise to move with "historic speed and strength", in his first weeks back in office President Donald ...